Cryoport, Inc. (CYRX)
Market Cap | 1.20B |
Revenue (ttm) | 233.36M |
Net Income (ttm) | -295.98M |
Shares Out | 49.00M |
EPS (ttm) | -6.39 |
PE Ratio | n/a |
Forward PE | 58.14 |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 191,578 |
Open | 24.73 |
Previous Close | 25.24 |
Day's Range | 24.35 - 25.24 |
52-Week Range | 15.63 - 45.36 |
Beta | 1.24 |
Analysts | Buy |
Price Target | 30.60 (+25.41%) |
Earnings Date | Feb 23, 2023 |
About CYRX
Cryoport, Inc., a life sciences services company, provides temperature-controlled logistics solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoportal, a cloud-based logistics management platform that supports the management of shipments, which includes order entry, document preparation, customs documentation, courier management, real-time shipment tracking and monitoring, issue resolution, and regulatory compliance requirements; and CryoPort Express Shippers, which is used to ensure that the... [Read more]
Financial Performance
In 2021, CryoPort's revenue was $222.61 million, an increase of 182.87% compared to the previous year's $78.70 million. Losses were -$283.72 million, 278.2% more than in 2020.
Financial StatementsAnalyst Forecast
According to 15 analysts, the average rating for CYRX stock is "Buy." The 12-month stock price forecast is $30.6, which is an increase of 25.41% from the latest price.
News

Cryoport Announces New Strategic Partnership with Syneos Health to Advance Cell & Gene Therapies
Partnership to Provide Cell and Gene Industry Integrated Solution including Cryoport's IntegriCell™ platform, and Supply Chain Services NASHVILLE, Tenn. , Jan. 18, 2023 /PRNewswire/ -- Cryoport, Inc. ...

Cryoport to Present at the J.P. Morgan 41st Annual Healthcare Conference
NASHVILLE, Tenn. , Dec. 20, 2022 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply chain solutions for the life sciences in...

CryoPort, Inc. (CYRX) Reports Q3 Loss, Misses Revenue Estimates
CryoPort, Inc. (CYRX) delivered earnings and revenue surprises of -15.38% and 13.89%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Cryoport Reports Results for the Third Quarter 2022
Third quarter revenue of $60.5 million; nine months 2022 revenue reaches $176.9 million; Cryoport Systems' revenue up 25% year-over-year $530 million in cash and short-term investments Supporting a re...

Cryoport to Report Third Quarter 2022 Financial Results on November 3, 2022
NASHVILLE, Tenn. , Oct. 27, 2022 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply chain solutions for the life sciences ind...

CryoPort, Inc. (CYRX) Stock Jumps 10.5%: Will It Continue to Soar?
CryoPort, Inc. (CYRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near te...

Cryoport Enters into Strategic Relationship with Takeda's BioLife Plasma Services
Cryoport plans to establish an integrated supply chain platform with BioLife Plasma Services to offer standardized cell therapy collection, processing, and storage services in United States and Europe...

Can CryoPort, Inc. (CYRX) Climb 36% to Reach the Level Wall Street Analysts Expect?
The mean of analysts' price targets for CryoPort, Inc. (CYRX) points to a 36.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among a...

CryoPort, Inc. (CYRX) Reports Q2 Loss, Lags Revenue Estimates
CryoPort, Inc. (CYRX) delivered earnings and revenue surprises of -13.33% and 0.40%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Cryoport Reports Results for the Second Quarter 2022
Record revenue of $64.2 million for the quarter, up 14% as reported and 18% at constant currency (year-over-year) Supporting a record 626 global clinical trials; a net of 17 new trials added during th...

Cryoport to Report Second Quarter 2022 Financial Results on August 4, 2022
NASHVILLE, Tenn. , July 28, 2022 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply chain solutions for the life sciences ind...

CryoPort, Inc. (CYRX) Reports Q1 Loss, Tops Revenue Estimates
CryoPort, Inc. (CYRX) delivered earnings and revenue surprises of -55% and 0.63%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Cryoport Reports First Quarter 2022 Results
Revenue of $52.3 million Provides Full Year 2022 Revenue Guidance of $260-$265 million Expansion and advancement of robust clinical pipeline continues – now supporting a record 609 clinical trials, wi...

Cryoport to Report First Quarter 2022 Financial Results on May 5, 2022
NASHVILLE, Tenn. , April 28, 2022 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply chain solutions for the life sciences in...

Cryoport Acquires Cell&Co BioServices
Acquisition of Cell&Co BioServices, Clermont-Ferrand, France, accelerates Company's EMEA expansion plans and development of its Global Supply Chain Network NASHVILLE, Tenn. , April 18, 2022 /PRNewswir...

Cryoport's MVE Biological Solutions' New Prague Manufacturing Plant Returns to Full Production
Company provides further update on financial impact of New Prague, MN fire NASHVILLE, Tenn., March 30, 2022 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a global leader...

Cryoport Authorizes $100 Million Repurchase Program
Management Presenting at Upcoming Investor Conferences NASHVILLE, Tenn., March 11, 2022 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a global leader in temperature-cont...

New Strong Sell Stocks for March 10th
BSET, CYRX, and DIN have been added to the Zacks Rank #5 (Strong Sell) List on March 10, 2022.

CryoPort, Inc. (CYRX) Reports Q4 Loss, Misses Revenue Estimates
CryoPort, Inc. (CYRX) delivered earnings and revenue surprises of -780% and 2.48%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Cryoport Reports Fourth Quarter and Full Year 2021 Results
NASHVILLE, Tenn., Feb. 24, 2022 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply chain solutions for the life sciences indu...

Here's Why CryoPort, Inc. (CYRX) is Poised for a Turnaround After Losing 22.8% in 4 Weeks
CryoPort, Inc. (CYRX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in rev...

CryoPort, Inc. (CYRX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
CryoPort, Inc. (CYRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Cryoport Report's Fourth Quarter and 2021 Financial Results on February 24, 2022
NASHVILLE, Tenn., Feb. 15, 2022 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply chain solutions for the life sciences indu...

Cryoport Provides Positive Update on MVE Biological Solution's New Prague Facility
NASHVILLE, Tenn., Feb. 9, 2022 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply chain solutions for the life sciences indus...

Cryoport Reports Fire Damage at MVE's New Prague Facility
NASHVILLE, Tenn., Jan. 31, 2022 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply chain solutions for the life sciences indu...